| Type |
Neuroendocrine interface |
| Location |
Third and fourth ventricles |
| Key Features |
Fenestrated capillaries, no blood-brain barrier |
| Brain Regions |
Median eminence, OVLT, SFO, AP, PI, SC |
| Disease Relevance |
Alzheimer's Disease, Parkinson's Disease, Neuroinflammation |
Circumventricular Organs is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Circumventricular organs (CVOs) are a collection of specialized neuroendocrine structures located along the walls of the third and fourth ventricles of the brain. Unlike most brain regions, CVOs possess fenestrated capillaries that lack a normal blood-brain barrier (BBB), allowing bidirectional communication between the central nervous system and peripheral blood circulation [1]. This unique feature makes CVOs critical interfaces for neuroendocrine regulation, autonomic control, and immune-brain communication.
The CVOs play essential roles in maintaining homeostasis by sensing circulating molecules (hormones, cytokines, toxins) that cannot normally cross the BBB and integrating this information into central neural circuits [2]. These structures have become increasingly recognized as important players in neurodegenerative diseases, where BBB dysfunction and neuroinflammation are hallmarks of disease progression.
¶ Anatomy and Classification
The circumventricular organs are classified into two categories based on their function: secretory CVOs (which release substances into the blood) and sensory CVOs (which sample blood-borne molecules).
The median eminence (ME) is located in the floor of the third ventricle and forms part of the hypothalamic-pituitary axis. It serves as the primary portal system through which hypothalamic releasing and inhibiting hormones access the anterior pituitary [3].
- Location: Floor of third ventricle, ventral hypothalamus
- Function: Portal system for hypothalamic-pituitary regulation
- Cell types: Tanycytes, portal capillary endothelial cells, pituitary hormone-secreting cells
- Disease relevance: Dysregulation of ME function affects cortisol, thyroid hormone, and growth hormone axes in neurodegeneration
The OVLT is located in the anterior wall of the third ventricle and functions as the primary osmoreceptor site in the brain [4].
- Location: Anterior wall of third ventricle, preoptic region
- Function: Osmoreception, sodium sensing, cardiovascular regulation
- Cell types: Neurons expressing osmosensitive transient receptor potential vanilloid (TRPV1) channels
- Disease relevance: Impaired osmoreception in AD and PD; autonomic dysfunction
The subfornical organ (SFO) is the most studied CVO and is crucial for cardiovascular and fluid balance [5].
- Location: Dorsal third ventricle, at the fornix junction
- Function: Angiotensin II sensing, thirst, sympathetic activation
- Cell types: Neurons expressing AT1 receptors for angiotensin II
- Disease relevance: Renin-angiotensin system dysregulation in AD and PD
The area postrema (AP) is the primary chemoreceptor trigger zone and is critical for emesis (vomiting) [6].
- Location: Floor of fourth ventricle, caudal medulla
- Function: Chemoreceptor trigger zone, emesis, nausea detection
- Cell types: Chemoreceptor neurons, GLP-1 expressing cells
- Disease relevance: Target for Parkinson's disease medication-induced nausea; gateway for peripheral immune signals
¶ Pineal Gland
The pineal gland (also called epiphysis) is a secretory CVO that produces melatonin and regulates circadian rhythms [7].
- Location: Dorsal diencephalon, posterior to third ventricle
- Function: Melatonin secretion, circadian rhythm regulation
- Cell types: Pinealocytes, supporting glial cells
- Disease relevance: Circadian disruption in AD and PD; melatonin as potential therapeutic
The subcommissural organ (SCO) is located beneath the posterior commissure and secretes glycoproteins into the cerebrospinal fluid [8].
- Location: Dorsal midbrain, beneath posterior commissure
- Function: CSF secretion, Reissner's fiber formation
- Cell types: Secretory ependymal cells
- Disease relevance: Less studied in neurodegeneration
The sensory CVOs lack secretory functions but contain specialized neurons that detect circulating molecules:
- SFO: Senses angiotensin II, sodium, and cardiovascular signals
- OVLT: Senses osmolality, sodium, and reproductive hormones
- AP: Senses toxins, drugs, and immune signals
The defining feature of CVOs is their fenestrated capillaries, which have:
- Endothelial pores (fenestrae): 50-80 nm diameter openings
- Lack of tight junctions: Between endothelial cells
- High vascular permeability: Allows molecules up to 70 kDa to pass
- Perivascular space: Surrounded by specialized glial processes
Despite lacking a classical BBB, CVOs express various transporters:
- GLUT1 glucose transporter: Glucose entry
- Amino acid transporters: Neutral amino acid transport
- Organic anion transporters: Drug and toxin clearance
- Receptor-mediated transcytosis: For larger molecules
CVOs integrate information through extensive neural connections:
- Hypothalamic nuclei: Preoptic area, paraventricular nucleus, supraoptic nucleus
- Brainstem: Solitary nucleus, dorsal motor nucleus of the vagus
- Thalamus: Midline and intralaminar nuclei
- Limbic system: Amygdala, hippocampus
CVOs serve as critical interfaces between the peripheral immune system and the central nervous system [9]:
- Immune signaling: Peripheral cytokines (IL-1β, IL-6, TNF-α) signal to brain through CVOs
- Neural-immune integration: CVO neurons project to hypothalamic and brainstem nuclei that control autonomic responses
- Systemic inflammation: CVOs amplify or dampen inflammatory responses in the brain
In neurodegenerative diseases, the distinction between CVOs and BBB-protected brain regions becomes blurred:
- Alzheimer's Disease: Progressive BBB breakdown allows peripheral molecules to enter normally protected brain regions [10]
- Parkinson's Disease: Leakage of the BBB in the substantia nigra and other regions
- BBB repair failure: Impaired repair mechanisms in CVOs may contribute to chronic neuroinflammation
CVOs are increasingly recognized in AD pathophysiology:
- Circadian disruption: Pineal gland dysfunction leads to altered melatonin secretion, affecting sleep-wake cycles and amyloid-beta clearance [11]
- Autonomic dysfunction: OVLT and SFO dysfunction contributes to cardiovascular dysregulation
- Immune activation: Area postrema-mediated immune-to-brain signaling may exacerbate neuroinflammation
- Fluid balance: Impaired osmoreception contributes to delirium and confusional states
CVOs play several roles in PD:
- Nausea and vomiting: The area postrema is the site where levodopa and other PD medications induce nausea [12]
- Autonomic failure: CVO dysfunction contributes to orthostatic hypotension and gastrointestinal issues
- Alpha-synuclein propagation: CVOs may serve as entry points for pathological alpha-synuclein from the gut [13]
- Blood-CSF barrier: The choroid plexus (a CVO-like structure) shows impaired function in PD
- Autoimmune components: CVOs may contribute to immune dysregulation in ALS
- Respiratory control: Area postrema dysfunction may affect breathing regulation
- Fluid homeostasis: Impaired osmoreception in ALS patients
- Autonomic failure: CVO dysfunction is central to MSA pathophysiology
- Cardiovascular dysregulation: SFO and OVLT abnormalities
- Circadian rhythms: Pineal gland involvement
CVOs offer unique opportunities for drug delivery:
- Targeted delivery: Drugs can be delivered through fenestrated capillaries
- Intranasal delivery: Nasally administered drugs may reach CVOs
- Peripheral-to-central signaling: Drugs acting on peripheral receptors can signal through CVOs
¶ Melatonin and Pineal Gland
- Melatonin supplementation: Used to improve sleep and potentially slow AD progression [14]
- Circadian entrainment: Light therapy targeting circadian circuits
- Antiemetics: 5-HT3 antagonists (ondansetron) and NK1 antagonists (aprepitant)
- GLP-1 analogs: May protect against neurodegeneration through area postrema signaling
- AT1 receptor blockers: May reduce neuroinflammation through SFO
- ACE inhibitors: Potential neuroprotective effects
- Tanycyte-based therapies: Targeting the median eminence for neural stem cell delivery
- CVO-specific drug delivery: Engineering drugs to cross fenestrated capillaries
- Immunomodulation: Modulating CVO-mediated immune-to-brain signaling
- Neuroimaging: MRI and PET to study CVO structure and function
- Electrophysiology: In vivo and in vitro recordings from CVO neurons
- Tracing studies: Viral tracing to map CVO neural connectivity
- Blood-CSF analysis: Comparing molecular composition in blood and CSF
- Postmortem studies: Histological examination of CVO tissue
- Transgenic models: APP/PS1 mice for AD, alpha-synuclein transgenic mice for PD
- ** lesion models**: Selective CVO lesions to test function
- Optogenetics: Cell-type-specific manipulation of CVO neurons
The study of Circumventricular Organs has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Duvernoy, H.M. (1999). The circumventricular organs: an atlas of their comparative anatomy and functional aspects. Progress in Brain Research 91:123-148. PMID:10508985
-
Gross, P.M. et al. (1990). Circumventricular organs: new views on their function. News in Physiological Sciences 5:121-125. DOI:10.1152/nips.1990.5.3.121
-
Rodriguez, E.M. et al. (2010). The median eminence as a neuroendocrine organ. Progress in Brain Research 181:1-16. PMID:20417834
-
McKinley, M.J. et al. (2003). The OVLT: osmoreceptor site for thirst. Progress in Brain Research 139:91-105. PMID:12666554
-
Ferguson, A.V. & Bains, J.S. (1996). Electrophysiology of the circumventricular organs. Frontiers in Neuroendocrinology 17:440-475. PMID:8905351
-
Miller, A.D. & Leslie, R.A. (1994). The area postrema and vomiting. Frontiers in Neuroendocrinology 15:301-320. PMID:7895853
-
Arendt, J. & Skene, D.J. (2005). Melatonin as a chronobiotic. Sleep Medicine Reviews 9:25-39. PMID:15649736
-
Rodriguez, E.M. et al. (1992). The subcommissural organ: a neuroendocrine gland. Microscopy Research and Technique 22:24-47. PMID:1378584
-
Banks, W.A. (2015). The blood-brain barrier in neuroimmunology. Journal of Neuroimmunology 278:1-3. PMID:25469791
-
Zlokovic, B.V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease. Journal of Clinical Investigation 121:4135-4147. PMID:22045556
-
Zhou, J.N. et al. (2003). Alterations in melatonin in Alzheimer's disease. Journal of Pineal Research 35:165-170. PMID:12932052
-
Dinu, A.R. et al. (2020). Area postrema and Parkinson's disease. Movement Disorders 35:195-208. PMID:31797483
-
Braak, H. et al. (2003). Staging of brain pathology in sporadic Parkinson's disease. Neurobiology of Aging 24:197-211. PMID:12498954
-
Lin, L. et al. (2013). Melatonin in Alzheimer's disease. Current Neuropharmacology 11:434-442. PMID:24381530